MapLight Therapeutics, Inc. (MPLT)
| Market Cap | 1.24B |
| Revenue (ttm) | n/a |
| Net Income | -161.15M |
| EPS | -18.56 |
| Shares Out | 45.34M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 292,228 |
| Open | 29.22 |
| Previous Close | 29.20 |
| Day's Range | 27.00 - 29.95 |
| 52-Week Range | 12.24 - 33.28 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 34.43 (+25.66%) |
| Earnings Date | May 28, 2026 |
About MPLT
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company’s products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer’s disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the treatment of motor deficits in Parkinson’s disease; ML-055 for the treatment of neuropsychiatric co... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for MPLT stock is "Strong Buy." The 12-month stock price target is $34.43, which is an increase of 25.66% from the latest price.
News
MapLight Therapeutics to Participate in Upcoming Investor Conferences
SAN FRANCISCO and BOSTON, May 08, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT) today announced that members of its management team will participate in the following investor con...
MapLight Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju initiated coverage of MapLight Therapeutics (MPLT) with a Buy rating and $45 price target MapLight is a clinical-stage biopharmaceutical company focused on i...
MapLight Therapeutics completes enrollment in ZEPHYR trial
MapLight Therapeutics (MPLT) announced completion of enrollment in its Phase 2 ZEPHYR trial evaluating ML-007C-MA for the treatment of schizophrenia. The company also announced completion of the final...
MapLight Therapeutics Announces Completion of Enrollment in ZEPHYR Phase 2 Trial and Updates Expected Timing of Topline Results
SAN FRANCISCO and BOSTON, May 01, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering f...
MapLight Therapeutics initiated with a Buy at Needham
Needham initiated coverage of MapLight Therapeutics (MPLT) with a Buy rating and $37 price target The firm believes the muscarinic class is likely to be “disruptive,” with application across multiple
MapLight Therapeutics initiated with a Buy at TD Cowen
TD Cowen initiated coverage of MapLight Therapeutics (MPLT) with a Buy rating and no price target The company is advancing candidates for the treatment of central nervous system and neuropsychic
MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
SAN FRANCISCO and BOSTON, March 26, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering...
Canaccord starts MapLight with Buy into schizophrenia data
Canaccord initiated coverage of MapLight Therapeutics (MPLT) with a Buy rating and $35 price target The company is developing novel therapeutics for central nervous system disorders, the analyst tells...
MapLight Therapeutics initiated with a Buy at Canaccord
Canaccord initiated coverage of MapLight Therapeutics (MPLT) with a Buy rating and $35 price target
MapLight Therapeutics expects topline results from ZEPHYR trial in Q3
MapLight Therapeutics (MPLT) announced an update to the expected timing of topline results for its ongoing Phase 2 ZEPHYR and IRIS clinical studies, which are progressing ahead of schedule. The
MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026
SAN FRANCISCO and BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (MapLight) (Nasdaq: MPLT) today announced an update to the expected timing of topline results for its ongoing Ph...
MapLight Therapeutics receives fast track designation for ML-007C-MA for ADP
MapLight Therapeutics (MPLT) announced that the U.S. Food and Drug Administration has granted Fast Track designation to ML-007C-MA, an investigational novel M1/M4 muscarinic agonist, for the treatment...
MapLight Therapeutics Receives Fast Track Designation for ML-007C-MA for Alzheimer's Disease Psychosis
SAN FRANCISCO and BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (“MapLight”) (Nasdaq: MPLT) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Tr...
MapLight Therapeutics, SandboxAQ announce strategic collaboration
SandboxAQ and MapLight Therapeutics (MPLT) announced that the companies have entered into a strategic collaboration to discover and develop potential first-in-class therapies targeting a novel G prote...
SandboxAQ and MapLight Therapeutics Announce Strategic Collaboration to Discover and Develop Novel CNS Therapies
SAN FRANCISCO and BOSTON, Dec. 16, 2025 (GLOBE NEWSWIRE) -- SandboxAQ and MapLight Therapeutics, Inc. (Nasdaq: MPLT) announced today that the companies have entered into a strategic collaboration to d...
MapLight Therapeutics reports Q3 EPS ($37.18) vs ($25.08) last year
“2025 was a year of exceptional execution and acceleration for MapLight,” said Chris Kroeger, Chief Executive Officer of MapLight Therapeutics (MPLT). “In the last year, we have made noteworthy progre...
MapLight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate Progress
Topline results from Phase 2 ZEPHYR trial of ML-007C-MA for schizophrenia expected in the second half of 2026 Topline results from Phase 2 VISTA trial of ML-007C-MA for Alzheimer's disease psychosis e...
ADEPT-2 news ‘at face is a win’ for MapLight Therapeutics, says Stifel
After Bristol Myers (BMY) announced this morning that the ADEPT-2 study of Cobenfy in in Alzheimer’s disease psychosis will continue enrolling additional patients after a review identified irregularit...
MapLight Therapeutics initiated with an Outperform at Leerink
Leerink analyst Marc Goodman initiated coverage of MapLight Therapeutics (MPLT) with an Outperform rating and $30 price target The firm is bullish on the muscarinic space and says MapLight’s lead
MapLight Therapeutics initiated with a Buy at Stifel
Stifel initiated coverage of MapLight Therapeutics (MPLT) with a Buy rating and $28 price target The firm sees the company as a potential second-mover in the muscarinic space. Despite the
MapLight Therapeutics initiated with a Buy at Jefferies
Jefferies analyst Andrew Tsai initiated coverage of MapLight Therapeutics (MPLT) with a Buy rating and $32 price target The company’s ML-007C-MA has a 30%-40% probability of success to generate superi...
MapLight Therapeutics initiated with an Overweight at Morgan Stanley
Morgan Stanley initiated coverage of MapLight Therapeutics (MPLT) with an Overweight rating and $34 price target The company’s lead asset, ML007-C-MA, has “best in class potential” in the greater than
MapLight Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN FRANCISCO and BOSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitati...
MapLight Therapeutics valued at $787 million as shares jump in Nasdaq debut
Shares of MapLight Therapeutics opened 11.8% above their offer price in their Nasdaq debut on Monday, giving the drug developer a $787 million valuation.
MapLight Therapeutics Announces Pricing of Initial Public Offering
SAN FRANCISCO and BOSTON, Oct. 26, 2025 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitati...